Empagliflozin Ameliorates Diabetic Cardiomyopathy by Inhibiting Ferroptosis via SIRT3: Mechanisms and Therapeutic Implications
Antioxidants · 24.04.2026 · 15 (5) · 543
DOI: 10.3390/antiox15050543 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antioxidants, online erschienen am 24.04.2026. Verfasst von Taoshan Feng und 9 weiteren Autor:innen. Beteiligte Einrichtung: Maternal and Child Research Institute, Shunde Women and Children Hospital, Guangdong Medical University, Foshan 528300, China. Die Arbeit nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Guangdong Basic and Applied Basic Foundation, Affiliated Hospital of Guangdong Medical College Hospital.
Abstract (Originalsprache)
Empagliflozin (EMPA), a sodium-glucose cotransporter 2 inhibitor, has garnered attention for its cardiovascular benefits beyond glycemic control. Ferroptosis, a novel form of regulated cell death, contributes to the pathogenesis of diabetic cardiomyopathy (DCM). However, whether EMPA mitigates DCM by suppressing ferroptosis remains unclear. Here, Type 2 diabetic db/db mice were used to establish a DCM model and treated with EMPA (10 mg/kg/day) for 12 weeks. EMPA significantly improved cardiac function, reduced myocardial fibrosis, and attenuated ferroptosis, concomitant with upregulated silent information regulator 3 (SIRT3) expression. In the rat cardiomyocytes (H9c2 cells) exposed to high glucose and palmitic acid, EMPA treatment or SIRT3 overexpression alleviated oxidative stress, mitochondrial dysfunction, and ferroptosis. Mechanistically, molecular docking, molecular dynamics simulation, cellular thermal shift assay and drug affinity responsive target stability assay confirmed that SIRT3 is the drug target of EMPA, stabilizing its protein levels and reducing acetylated p53 expression. Notably, SIRT3 silencing abolished EMPA’s beneficial effects on oxidative stress and ferroptosis. Our findings demonstrate that EMPA exerts cardioprotective effects by inhibiting oxidative stress and ferroptosis in cardiomyocytes, which is mediated by SIRT3. This study provides novel insights into the mechanisms underlying EMPA’s therapeutic effects in DCM.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Maternal and Child Research Institute, Shunde Women and Children Hospital, Guangdong Medical University, Foshan 528300, China.
- Department of Endocrinology, The Second Affiliated Hospital of Guangdong Medical University, Zhanjiang 524000, China.
- Department of Pulmonary Oncology, Affiliated Hospital of Guangdong Medical University, Zhanjiang 524000, China.
- Faculty of Chinese Medicine, Macau University of Science and Technology, Macau 999078, China.
ORCID-Profile: Xusan Xu, Zhengqiang Luo, Wensen Zhang, Yajun Wang, Xiaoming Chen
Förderung
- National Natural Science Foundation of China
- Guangdong Basic and Applied Basic Foundation
- Affiliated Hospital of Guangdong Medical College Hospital
- Guangdong Medical College
- Affiliated Hospital of Guangdong Medical University Clinical Research Program
- Affiliated Hospital of Guangdong Medical University
- Clinical+Basic Innovation Project of Guangdong Medical University
Zitieren
APA
Feng, T., Liu, M., Zhong, D., Xu, X., Luo, Z., Zhang, W., Wang, Y., Chen, R., Chen, X., & Ma, G. (2026). Empagliflozin Ameliorates Diabetic Cardiomyopathy by Inhibiting Ferroptosis via SIRT3: Mechanisms and Therapeutic Implications. Antioxidants, 15(5), 543. https://doi.org/10.3390/antiox15050543
Vancouver
Feng T, Liu M, Zhong D, Xu X, Luo Z, Zhang W, et al. Empagliflozin Ameliorates Diabetic Cardiomyopathy by Inhibiting Ferroptosis via SIRT3: Mechanisms and Therapeutic Implications. Antioxidants. 2026;15(5):543. doi:10.3390/antiox15050543
BibTeX
@article{Feng2026,
author = {Feng, Taoshan and Liu, Meilian and Zhong, Dan and Xu, Xusan and Luo, Zhengqiang and Zhang, Wensen and Wang, Yajun and Chen, Riling and Chen, Xiaoming and Ma, Guoda},
title = {Empagliflozin Ameliorates Diabetic Cardiomyopathy by Inhibiting Ferroptosis via SIRT3: Mechanisms and Therapeutic Implications},
journal = {Antioxidants},
year = {2026},
volume = {15},
number = {5},
pages = {543},
doi = {10.3390/antiox15050543}
}
EUVIMED